Effects of Autogenic Drainage and Flutter Device in COPD (NCT07713043) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Effects of Autogenic Drainage and Flutter Device in COPD
Pakistan42 participantsStarted 2026-06
Plain-language summary
COPD is a progressive lung disease that includes emphysema and chronic bronchitis and is a major cause of morbidity and mortality worldwide. Airway clearance techniques help improve mucus removal, reduce dyspnea, and enhance quality of life in COPD patients. This study aims to compare the effects of autogenic drainage and flutter device on dyspnea, pulmonary function, and functional capacity in patients with COPD. A randomized clinical trial will be conducted at Gulab Devi Teaching Hospital using convenient sampling. Participants will be divided into two groups: Group A will receive autogenic drainage, while Group B will use the flutter device. Interventions will be performed daily for 20-30 minutes over 6 weeks. Outcome measures will include dyspnea severity scale, spirometry, and 6-minute walk test. Data will be analyzed using SPSS with significance set at p \< 0.05. The study may provide evidence for effective, non-invasive, and cost-effective management strategies for COPD patients.
Who can participate
Age range
40 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age group: Middle age adults (40-60 years), medically stable
* Both gender
* Diagnosis based on GOLD criteria ((FEV₁/FVC ratio \< 0.70).
* Moderate COPD with no acute exacerbations in the past 4-6 weeks.
* Participants must be able to perform Autogenic drainage and Flutter device physically and mentally.
* Voluntary participation with consent.
Exclusion Criteria:
* Cardic Diseases (Acute MI, Congestive Heart Failure)
* Musculoskeletal Impairements
* Using Non-invasive Ventilation
* Recent lung diseases (Respiratory failure, pneumothorax)
* Hemodynamic instability
* Uncoorperative patients
* Cognitive Impairement scale
* Participants excluded if they did not consent
* Comorbidities affecting exercise tolerance
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Dyspnea
Timeframe: Baseline and after 6 weeks of intervention
2
Forced Vital Capacity
Timeframe: Baseline and after 6 weeks of intervention
3
Forced Expiratory Volume in One Second
Timeframe: Baseline and after 6 weeks of intervention
4
FEV₁/FVC ratio
Timeframe: Baseline and after 6 weeks of intervention
5
Peak Expiratory Flow
Timeframe: Baseline and after 6 weeks of intervention